Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

(2009) Constantine S. Tam et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin

(2009) Mark A. Dawson et al.   NATURE

The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms

(2008) C. S. Tam et al.   BLOOD

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML

(2008) Y. Jiang et al.   BLOOD

Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders

(2008) Daniela Capello et al.   BRITISH JOURNAL OF HAEMATOLOGY

Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders

(2008) N. Fourouclas et al.   HAEMATOLOGICA

5-Azacitidine has limited therapeutic activity in myelofibrosis

(2008) R A Mesa et al.   LEUKEMIA

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis

(2008) A Quintás-Cardama et al.   LEUKEMIA

Hypermethylation ofCXCR4Promoter in CD34+Cells from Patients with Primary Myelofibrosis

(2008) Costanza Bogani et al.   STEM CELLS